ArticleNature communications2025
Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target.
Abstract read
In one paragraph
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Single-cell sequencing reveals transcriptional and immunogenetic diversity in stereotyped chronic lymphocytic leukemia.Blood neoplasia · 2026Article
- Monocyte Galectin-9 is associated with CD8⁺ T-cell dysfunction and early relapse after haploidentical hematopoietic stem cell transplantation.Biomarker research · 2026Article
- Circulating Extracellular Vesicle Biomarkers in Chronic Lymphocytic Leukemia: A Preliminary Study on Their Diagnostic, Prognostic, and Predictive Relevance.Biomolecules · 2026Article
- High-dimensional spectral flow cytometry uncovers progressive T-cell exhaustion and myeloid cell reprogramming in a CLL mouse model.HemaSphere · 2026Article
- Spatial Immune Coding in Tumor-Draining Lymph Nodes: Functional Compartmentalization of Immune Activation and Immunosuppression.International journal of molecular sciences · 2026Review
- Article
- Galectin-9-driven immune evasion constrains radiotherapy-induced systemic antitumor immunity.Journal for immunotherapy of cancer · 2026Article
- New-Onset Vitiligo During Dupilumab Treatment: A Clinical Observation and Literature Review.The clinical respiratory journal · 2026Review
- Review
- CCL19bioRxiv : the preprint server for biology · 2026Article
- LGALS9 blockade augments vaccine-induced immune responses against prostate cancer.Journal for immunotherapy of cancer · 2026Article
- Advancing Immunotherapy in Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2026Review
- The signature of pyroptosis-related gene diagnosis and immune microenvironment in preeclampsia.BMC pregnancy and childbirth · 2026Article
- Multi-omics analysis reveals that CAPG positive macrophages are key immunosuppressive drivers and prognostic determinants in the ferroptosis landscape of hepatocellular carcinoma.Discover oncology · 2026Article
- Mechanisms of T cell activation: Integrating signaling pathways, experimental models, and therapeutic implications.EXCLI journal · 2026Review
- Pre-treatment T cell features and immune-milieu characteristics shape treatment-induced exhaustion and resistance to Blinatumomab in B-cell acute lymphoblastic leukemia.Frontiers in immunology · 2026Article
- A Transcriptional Map of Human Tonsil Architecture: Beyond the Sum of (Single Cell) Parts.European journal of immunology · 2026Article
- TGF-β in hematologic malignancies: molecular functions and clinical applications.Frontiers in immunology · 2026Review
- Single-cell RNA sequencing unravels T cell exhaustion underlying the chronicity of chromoblastomycosis.Frontiers in immunology · 2026Article
- Development and validation of a machine-learning-based triage model incorporating systemic inflammatory, nutritional, coagulation, and tumor marker parameters for identifying baseline distant metastasis in lung cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
L Llaó-Cid *Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0003-0543-6084
Jkl Wong *Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
I Fernandez BotanaTumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Y PaulDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2312-2954
M WierzTumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
L-M PilgerDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
A FloerchingerDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
C L TanCCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2529-1030
S GonderTumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
G PaganoTumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
M ChazotteInstitute for Computational Biomedicine, Faculty of Medicine, Heidelberg University and Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0009-0007-4901-5173
K BestakInstitute for Computational Biomedicine, Faculty of Medicine, Heidelberg University and Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0009-0009-8245-9846
C SchifflersDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2266-8621
M IskarDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-8603-4313
T RoiderDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6973-3531
F CzernilofskyDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5868-2890
P-M BruchDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-9992-3109
J P MallmscOpenLab, German Cancer Research Center, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7059-4030
A CosmaNational Cytometry Platform, Luxembourg Institute of Health, Luxembourg, Luxembourg.ORCID http://orcid.org/0000-0002-3686-8034
D E CamptonRareCyte, Seattle, WA, USA.
E Gerhard-HartmannInstitute for Pathology, University of Würzburg, Würzburg, Germany.
A RosenwaldInstitute for Pathology, University of Würzburg, Würzburg, Germany.
D ColomerInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hematopathology Unit, Hospital Clinic, CIBERONC, Barcelona, Spain.ORCID http://orcid.org/0000-0001-7486-8484
E CampoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hematopathology Unit, Hospital Clinic, CIBERONC, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9850-9793
D SchapiroInstitute for Computational Biomedicine, Faculty of Medicine, Heidelberg University and Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-9391-5722
E W GreenCCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-1922-2298
S DietrichDepartment of Internal Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-0648-1832
P LichterDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
E Moussay *Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.ORCID http://orcid.org/0000-0002-0879-8067
J Paggetti *Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.ORCID http://orcid.org/0000-0001-9460-5876
M Zapatka *Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-8287-5967
M Seiffert *Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.seiffert@dkfz.de.ORCID http://orcid.org/0000-0001-5155-663X
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) INST 35/1597-1 FUGGDeutsche Krebshilfe (German Cancer Aid) 70114114"la Caixa" Foundation (Caixa Foundation) CLLSYSTEMS LCF/PR/HR22/52420015 (HR22-00172)
Abstract
T-cell exhaustion contributes to immunotherapy failure in chronic lymphocytic leukemia (CLL). Here, we analyze T cells from CLL patients' blood, bone marrow, and lymph nodes, as well as from a CLL mouse model, using single-cell RNA sequencing, mass cytometry, and tissue imaging. T cells in CLL lymph nodes show the most distinct profiles, with accumulation of regulatory T cells and CD8
Indexed as
GalectinsLeukemia, Lymphocytic, Chronic, B-CellT-Lymphocytes, RegulatoryAnimalsCD8-Positive T-LymphocytesDisease Models, AnimalFemaleHepatitis A Virus Cellular Receptor 2HumansImmunotherapyLymph NodesMaleMiceMultiomicsgalectin 9, mouseGalectinsHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2LGALS9 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.